One more time, our study remains limited due to the cross-sectional nature of our approaches; hence, we propose to conduct longitudinal monitoring of SLE patients to assess and/or validate the utility of IgA subtypes as new clinical biomarkers. The gene discussed is CD79A; the disease is systemic lupus erythematosus.